Advertisement
Advertisement

Update to Interim Guidance for Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for Injecting Drug Users

June 14, 2013

 < Prev  |  1  |  2 

References

  1. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection among people who inject drugs in Bangkok, Thailand: a randomized, double-blind, placebo-controlled trial. Lancet. In press, June 2013.
  2. CDC. Estimated HIV incidence in the United States, 2007-2010. HIV surveillance supplemental report 2012;17(4).
  3. CDC. HIV infection and HIV-associated behaviors among injecting drug users -- 20 cities, United States, 2009. MMWR 2012;61:133-8.
  4. Grant RM, Lama JR, Anderson PL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.
  5. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
  6. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423-34.
  7. Van Damme L, Corneli A, Ahmed K, et al. Pre-exposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-22.
  8. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003) [Abstract]. Presented at the 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA.
  9. CDC. Interim guidance: pre-exposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR 2011;60:65-8.
  10. CDC. Interim guidance for clinicians considering the use of pre-exposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR 2012;61:586-9.
  11. Food and Drug Administration. Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2012.
  12. CDC. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR 2012;61(No. RR-5).
  13. Edelman EJ, Fiellin DA. Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine. Am J Prev Med 2013;44(1 Suppl 2):S86-90.


TABLE. Results From Randomized, Placebo-Controlled, Clinical Trials of the Efficacy of Daily Oral Antiretroviral Pre-Exposure Prophylaxis (PrEP) for Preventing Human Immunodeficiency Virus (HIV) Infection

Clinical Trial

Participants

Type of Medication

mITT Efficacy*

Adherence-Adjusted Efficacy Based on TDF Detection in Blood

%

(95% CI)

%

(95% CI)

Bangkok Tenofovir Study

Injecting drug users

TDF

49

(10-72)

70

(2-91)

Partners PrEP

HIV discordant couples

TDF

67

(44-81)

86

(67-94)

TDF/FTC

75

(55-87)

90

(58-98)

TDF2

Heterosexually active men and women

TDF/FTC

62

(22-83)

84

NS

iPrEx

Men who have sex with men

TDF/FTC

42

(18-60)

92

(40-99)

Fem-PrEP

Heterosexually active women

TDF/FTC

NS

--

NA

--

VOICE

Heterosexually active women

TDF

NS

--

NA

--

TDF/FTC

NS

--

NA

--

Abbreviations: mITT = modified intent to treat analysis, excluding persons determined to have had HIV infection at enrollment; CI = confidence interval; TDF = tenofovir disoproxil fumarate; FTC = emtricitabine; NS = not statistically significant; NA = data not available.

* % reduction in acquisition of HIV infection.

 < Prev  |  1  |  2 



This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication Morbidity and Mortality Weekly Report. Visit the CDC's website to find out more about their activities, publications and services.
 
See Also
Study Finds First Evidence That PrEP Can Reduce HIV Risk Among People Who Inject Drugs
Bangkok Tenofovir Study: PrEP for HIV Prevention Among People Who Inject Drugs
iPrEx Welcomes CDC's Bangkok Tenofovir Study Showing Pre-Exposure Prophylaxis (PrEP) Is Safe and Effective for HIV Prevention in Injection Drug Users

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement